ROCKVILLE, Md., April 23, 2009 (GLOBE NEWSWIRE) -- Cytomedix, Inc. (NYSE Amex:GTF), today announced that it will be exhibiting at the 22nd Annual Symposium on Advanced Wound Care and Wound Healing Society (SAWC/WHS) Meeting from April 26 through April 29, 2009 at the Gaylord Texan Hotel and Convention Center in Dallas, TX. Two clinical posters which demonstrate positive outcomes of the AutoloGel(tm) System in challenging chronic wound patients will be presented during the symposium.
"We are very pleased to be participating in the SAWC/WHS Meeting," said Martin Rosendale, Chief Executive Officer of Cytomedix. "In early 2009, we implemented a new sales approach for the AutoloGel System, based on the scientific rationale for the mechanism of action, which will be the centerpiece of our exhibit. Additionally, we incorporated an intensive clinical support program for our new and existing customers. This approach has garnered acceptance by clinicians, which we are eager to build on at the SAWC/WHS Meeting. We are also particularly grateful that two reputable medical professionals will be sharing the encouraging results of their independent research on our products in the form of poster presentations," continued Rosendale. "We believe the increasing portfolio of positive clinical evidence is indicative of growing awareness and confidence in the AutoloGel(tm) technology by the medical community," he added.
The SAWC/WHS Meeting is the largest gathering of multidisciplinary wound care clinicians in the United States. The conference targets physicians, nurses, physical therapists, researchers, podiatrists, dieticians, and members of the medical industry involved in wound healing or wound care issues. The conference provides attendees with state-of-the-art reviews of clinical issues and research information.
The two abstract presentations were supported by an educational grant from Cytomedix, and will be available via the respective links below beginning April 26, 2009:
Using Platelet Rich Plasma (PRP) Gel to Manage Complex Wounds in an LTAC Theresa Hernandez, RN, CWS, Wound Care Coordinator; James C. Stern, DSACS LTAC Hospital, Hollywood, FL Link: http://www.cytomedix.com/abstract-usingPRP_2009-0426.html "Double impact": Synergism in using Negative Pressure Wound Therapy with alternated applications of Autologous Platelet-Derived Growth Factors in treating post acute surgical wounds. Case series L. Gurvich, ANP, MS, MPH, CWS L.Weiss Memorial Hospital, Wound Healing Center Chicago, Illinois Link: http://www.cytomedix.com/abstract-doubleimpact_2009-0426.html
ABOUT CYTOMEDIX
Cytomedix is a biotechnology company that develops, sells, and licenses regenerative biological therapies, including the AutoloGel(tm) System, a device for the production of platelet rich plasma ("PRP") gel derived from the patient's own blood. The AutoloGel(tm) System is cleared by the Food and Drug Administration ("FDA") for use on a variety of exuding wounds. Additional information regarding Cytomedix is available at: http://www.cytomedix.com
SAFE HARBOR STATEMENT
Statements contained in this press release not relating to historical facts are forward-looking statements that are intended to fall within the safe harbor rule for such statements under the Private Securities Litigation Reform Act of 1995. The information contained in the forward-looking statements is inherently uncertain, and Cytomedix's actual results may differ materially due to a number of factors, many of which are beyond Cytomedix's ability to predict or control, including among others, commercial success or acceptance of the Company's products by the medical community, competitive responses, viability and effectiveness of the Company's sales approach and overall marketing strategies, and Cytomedix's ability to execute on its strategy to market the AutoloGel(tm) System as contemplated. These forward-looking statements are subject to known and unknown risks and uncertainties that could cause actual events to differ from the forward-looking statements. More information about some of these risks and uncertainties may be found in the reports filed with the Securities and Exchange Commission by Cytomedix, Inc. Cytomedix operates in a highly competitive and rapidly changing business and regulatory environment, thus new or unforeseen risks may arise. Accordingly, investors should not place any reliance on forward-looking statements as a prediction of actual results. Except as is expressly required by the federal securities laws, Cytomedix undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, changed circumstances or future events or for any other reason.